Biocon net zooms 86% in first quarter
"Robust performance by biologics and small molecules business segments fuelled the growth in the first quarter. Investments in biosimilars are delivering expected results," said Biocon Chairperson Kiran Mazumdar-Shaw in a statement later here.
Biocon on Thursday reported Rs 206-crore consolidated net profit for the first quarter (Q1) of fiscal 2019-20, Photo: www.biocon.com